The DOI matches its Crossref record; the references it cites are not checked yet.
Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk
Open accessAbstract
Aims: Hypertriglyceridaemia is associated with increased risk of cardiovascular events. This clinical trial evaluated olezarsen, an N-acetyl-galactosamine-conjugated antisense oligonucleotide targeted to hepatic APOC3 mRNA to inhibit apolipoprotein C-III (apoC-III) production, in lowering triglyceride levels in patients at high risk for or with established cardiovascular disease. Methods and results: A randomized, double-blind, placebo-controlled, dose-ranging study was conducted in 114 patients with fasting serum triglycerides 200–500 mg/dL (2.26–5.65 mmol/L). Patients received olezarsen (10 or 50 mg every 4 weeks, 15 mg every 2 weeks, or 10 mg every week) or saline placebo subcutaneously for 6–12 months. The primary endpoint was the percent change in fasting triglyceride levels from baseline to Month 6 of exposure. Baseline median (interquartile range) fasting triglyceride levels were 262 (222–329) mg/dL [2.96 (2.51–3.71) mmol/L]. Treatment with olezarsen resulted in mean percent triglyceride reductions of 23% with 10 mg every 4 weeks, 56% with 15 mg every 2 weeks, 60% with 10 mg every week, and 60% with 50 mg every 4 weeks, compared with increase by 6% for the pooled placebo group (P-values ranged from 0.0042 to <0.0001 compared with placebo). Significant decreases in apoC-III, very low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B were also observed. There were no platelet count, liver, or renal function changes in any of the olezarsen groups. The most common adverse event was mild erythema at the injection site. Conclusion: Olezarsen significantly reduced apoC-III, triglycerides, and atherogenic lipoproteins in patients with moderate hypertriglyceridaemia and at high risk for or with established cardiovascular disease. Trial registration number: NCT03385239.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Compared with placebo, triglyceride levels were significantly reduced in patients receiving siRNA targeting ANGPTL3 (MD, −50.8%; 95% CI, −71.5 to −30.1)”
From Efficacy and safety of small interfering RNA (siRNA) therapies for hypertriglyceridemia and mixed dyslipidemia: an updated systematic review and meta-analysis (2026) · cites this paper as Tardif et al., 2022
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Compared with placebo, the pooled mean difference in LDL-C was −3.7% (95% CI, −10.4 to 3.1; I2 = 69.1%), indicating a not statistically significant reduction in LDL-C with small interfering RNA therapy (Figure 3A).”
From Efficacy and safety of small interfering RNA (siRNA) therapies for hypertriglyceridemia and mixed dyslipidemia: an updated systematic review and meta-analysis (2026) · cites this paper as Tardif et al., 2022
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Compared with placebo, VLDL-C levels were significantly reduced in patients receiving siRNA targeting ANGPTL3 (MD, −41%; 95% CI, −52.8 to −29.1)”
From Efficacy and safety of small interfering RNA (siRNA) therapies for hypertriglyceridemia and mixed dyslipidemia: an updated systematic review and meta-analysis (2026) · cites this paper as Tardif et al., 2022
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A similar trial design enrolling 114 patients with established CVD and elevated triglycerides demonstrated an up to − 60% reduction in triglyceride levels [176].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [176]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Olezarsen is an investigational GalNAc 3 -conjugated antisense oligonucleotide that reduces apolipoprotein C-III production by binding to APOC3 mRNA and inducing its degradation through ribonuclease H1-mediated cleavage of the sense strand. 26,28,29”
From Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome (2024) · cites this paper as [29]
Experimental — accuracy not yet measured
17 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 36 · Cited by 210
Metadata
- Authors
- Tardif, J.-C., Karwatowska-Prokopczuk, E., Amour, E. S., Ballantyne, C. M., Shapiro, M. D., Moriarty, P. M., Baum, S. J., Hurh, E., Bartlett, V. J., Kingsbury, J., Figueroa, A. L., Alexander, V. J., Tami, J., Witztum, J. L., Geary, R. S., O’Dea, L. S. L., Tsimikas, S., & Gaudet, D.
- Affiliations
- Montreal Heart Institute (CA)
- Akcea Therapeutics , 55 Cambridge Parkway Suite 100 Cambridge, Boston, MA 02142, USA
- Eric St-Amour, MD 214 Cite des jeunes Gatineau , QC J8Y 6S8, Canada
- Baylor College of Medicine (US)
- Wake Forest University Health Sciences (US)
- University of Kansas Medical Center (US)
- Florida Atlantic University (US)
- Ionis Pharmaceuticals (United States) (US)
- University of California San Diego (US)
- Université de Montréal (CA)
- Corresponding author
- Tardif, Jean-Claude
- Tsimikas, Sotirios
- ORCID
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-01-13
- Volume
- 43
- Issue
- 14
- Pages
- 1401-1412
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- PMC
- PMC8986458
- OpenAlex
- W4205868548
- Semantic Scholar
- 30b5e50d7269caf9ece15fa3d3128a4b5d6e8776
- Cited by
- 210
- References
- 36
- Citations by year
- 2026: 36 · 2025: 47 · 2024: 60 · 2023: 36 · 2022: 30
- FWCI
- 21.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- European Heart Journal (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc)
- Funders
- Akcea Therapeutics
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- olezarsen, apolipoprotein C-III, hypertriglyceridemia, antisense oligonucleotides, triglyceride lowering, cardiovascular risk, atherogenic lipoproteins, VLDL cholesterol, non-HDL cholesterol, apolipoprotein B, dose-ranging
- MeSH terms
- Heart Disease Risk Factors, Cardiovascular Diseases, Cholesterol, Humans, Lipoproteins, Risk Factors, Triglycerides, Hypertriglyceridemia, Apolipoprotein C-III
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. https://app.cochat.ai/papers/10.1093/eurheartj/ehab820
- The paper
- Tardif, J.-C., Karwatowska-Prokopczuk, E., Amour, E. S., Ballantyne, C. M., Shapiro, M. D., Moriarty, P. M., Baum, S. J., Hurh, E., Bartlett, V. J., Kingsbury, J., Figueroa, A. L., Alexander, V. J., Tami, J., Witztum, J. L., Geary, R. S., O’Dea, L. S. L., Tsimikas, S., & Gaudet, D. (2022). Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. European Heart Journal. https://doi.org/10.1093/eurheartj/ehab820
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.